and j and j grew the fastest with new medicines like invokeana and zer elto and other things for inflammatory diseases. >> j and j's performance is driven by say strong pharmaceutical business. people are concerned about that going forward. they have competition in hepatitis c and concerns about rammic aid which is 15% of the company's business as it relates to patent disputes as well as bio similars. >> and as investors question the pharma business it is the company's medical devices unit that is lagging. it was the only unit of the three to decline on an operational business in the first quarter. in march they sold courtis to health for $2 billion. >> they have been focused on getting out of the lower, slower-growth, lower operating margin portion of the business and will they in fact do m&a and pharma. >> as j&j slims down the question is will it expand in othe the company has more than $30 billion in cash causing some analysts to wo whet plans to make a large acquisition. we may get more insight next month when it hosts the analyst month focusing on the fastest part of the business. for "